FdaApplication
NDA 211988
Identifiers
- fda_app_no: NDA211988
Properties
| Property | Value |
|---|---|
| applicant_name | HERON THERAPEUTICS INC |
| application_type | NDA |
| approval_date | 2021-05-12 |
Revenue by product
ZYNRELEF KIT
| Period | Revenue |
|---|---|
| Q2 2026 | $11.1M* |
| Q1 2026 | $10.2M* |
| Q4 2025 | $12.5M* |
| Q3 2025 | $9.3M* |
| Q2 2025 | $8.2M* |
| Q1 2025 | $8.0M* |
| Q4 2024 | $8.5M* |
| Q3 2024 | $6.2M* |
| Q2 2024 | $5.8M* |
| Q1 2024 | $5.0M* |
| Q4 2023 | $5.7M* |
| Q3 2023 | $4.4M* |
| Q2 2023 | $4.1M* |
| Q1 2023 | $3.5M* |
| Q4 2022 | $3.9M* |
| Q3 2022 | $2.7M* |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (4)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| ZYNRELEF KIT | BUPIVACAINE; MELOXICAM | 400MG/14ML (29.25MG/ML);12MG/14ML (0.88MG/ML) | SOLUTION, EXTENDED RELEASE;PERIARTICULAR |
| ZYNRELEF KIT | BUPIVACAINE; MELOXICAM | 200MG/7ML (29.25MG/ML);6MG/7ML (0.88MG/ML) | SOLUTION, EXTENDED RELEASE;PERIARTICULAR |
| ZYNRELEF KIT | BUPIVACAINE; MELOXICAM | 60MG/2.3ML (29.25MG/ML);1.8MG/2.3ML (0.88MG/ML) | SOLUTION, EXTENDED RELEASE;PERIARTICULAR |
| ZYNRELEF KIT | BUPIVACAINE; MELOXICAM | 300MG/10.5ML (29.25MG/ML);9MG/10.5ML (0.88MG/ML) | SOLUTION, EXTENDED RELEASE;PERIARTICULAR |
4 products